- Home
- FLUX vs ABOS Comparison
FLUX vs ABOS Comparison
Compare FLUX & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLUX
- ABOS
- Stock Information
- Founded
- FLUX N/A
- ABOS 1996
- Country
- FLUX United States
- ABOS United States
- Employees
- FLUX N/A
- ABOS N/A
- Industry
- FLUX Industrial Machinery/Components
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- FLUX Miscellaneous
- ABOS Health Care
- Exchange
- FLUX Nasdaq
- ABOS Nasdaq
- Market Cap
- FLUX 98.5M
- ABOS 113.9M
- IPO Year
- FLUX N/A
- ABOS 2021
- Fundamental
- Price
- FLUX $2.37
- ABOS $2.21
- Analyst Decision
- FLUX Strong Buy
- ABOS Strong Buy
- Analyst Count
- FLUX 2
- ABOS 3
- Target Price
- FLUX $6.00
- ABOS $8.00
- AVG Volume (30 Days)
- FLUX 989.0K
- ABOS 433.2K
- Earning Date
- FLUX 09-16-2025
- ABOS 11-11-2025
- Dividend Yield
- FLUX N/A
- ABOS N/A
- EPS Growth
- FLUX N/A
- ABOS N/A
- EPS
- FLUX N/A
- ABOS N/A
- Revenue
- FLUX $66,434,000.00
- ABOS N/A
- Revenue This Year
- FLUX $8.23
- ABOS N/A
- Revenue Next Year
- FLUX $24.72
- ABOS N/A
- P/E Ratio
- FLUX N/A
- ABOS N/A
- Revenue Growth
- FLUX 9.22
- ABOS N/A
- 52 Week Low
- FLUX $1.15
- ABOS $0.86
- 52 Week High
- FLUX $7.55
- ABOS $3.36
- Technical
- Relative Strength Index (RSI)
- FLUX 33.10
- ABOS 59.51
- Support Level
- FLUX $5.06
- ABOS $1.85
- Resistance Level
- FLUX $7.55
- ABOS $2.46
- Average True Range (ATR)
- FLUX 0.93
- ABOS 0.21
- MACD
- FLUX -0.49
- ABOS -0.01
- Stochastic Oscillator
- FLUX 2.45
- ABOS 59.02
About FLUX Flux Power Holdings Inc.
Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.